All News


All series


All All News

I was first diagnosed with cancer when I was six years old, and I can still remember passing the time during treatment by listening to the “weekly top 40” that my brother and I recorded on a cassette tape.

The Food and Drug Administration (FDA) granted accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to the agency.

The Food and Drug Administration (FDA) approved BRACAnalysis CDx to be used to identify patients with advanced ovarian cancer who have germline BRCA mutations and are eligible for first line treatment with Lynparza (olaparib) after responding to platinum-based chemotherapy.

When a diagnosis begins to improve, it is hard to reconcile your identity as a patient with your identity as a whole. Grappling with questions of who you are after having been diagnosed with something life altering can be both profound and challenging, and leave you a bit, well, ambivalent.

The FDA has approved Herzuma (trastuzumab-pkrb) (Herzuma) as a biosimilar to Herceptin (trastuzumab, Genentech). Trastuzumab-pkrb is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer.

Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.

I try so hard to be positive, but in the back of my mind, I am constantly waiting for the other shoe to drop, for my blood counts to worsen, for the results of the next bone marrow biopsy to be haywire, for the chemo with its side effects to be administered, intensified or changed.